Development of potent antibody drug conjugates against ICAM1⁺ cancer cells in preclinical models of cholangiocarcinoma.

ABSTRACT: As a highly lethal adenocarcinoma of the hepatobiliary system, outcomes for cholangiocarcinoma (CCA) patients remain prominently poor with a 5-year survival of <10% due to the lack of effective treatment modalities. Targeted therapeutics for CCA are limited and surgical resection of CCA frequently suffers from a high recurrence rate. Here we report two effective targeted therapeutics in this preclinical study for CCA. We first performed a quantitative and unbiased screening of cancer-related antigens using comparative flow cytometry in a panel of human CCA cell lines, and identified intercellular adhesion molecule-1 (ICAM1) as a therapeutic target for CCA. After determining that ICAM1 has the ability to efficiently mediate antibody internalization, we constructed two ICAM1 antibody-drug co

SUBMITTER: Zhu B 

PROVIDER: S-EPMC10505223 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature